title: Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells.
abstract: Dendritic cells (DCs) play a critical role in the generation of adaptive immunity via the efficient capture, processing, and presentation of antigen (Ag) to naïve T cells. Administration of Ag-pulsed DCs is also an effective strategy for enhancing immunity to tumors and infectious disease organisms. Studies have also demonstrated that targeting Ags to Fcγ receptors (FcγR) on Ag presenting cells can enhance humoral and cellular immunity in vitro and in vivo. Specifically, our studies using a Francisella tularensis (Ft) infectious disease vaccine model have demonstrated that targeting immunogens to FcγR via intranasal (i.n.) administration of monoclonal antibody (mAb)-inactivated Ft (iFt) immune complexes (ICs) enhances protection against Ft challenge. Ft is the causative agent of tularemia, a debilitating disease of humans and other mammals and a category A biothreat agent for which there is no approved vaccine. Therefore, using iFt Ag as a model immunogen, we sought to determine if ex vivo targeting of iFt to FcγR on DCs would enhance the potency of i.n. administered iFt-pulsed DCs. In this study, bone marrow-derived DCs (BMDCs) were pulsed ex vivo with iFt or mAb-iFt ICs. Intranasal administration of mAb-iFt-pulsed BMDCs enhanced humoral and cellular immune responses, as well as protection against Ft live vaccine strain (LVS) challenge. Increased protection correlated with increased iFt loading on the BMDC surface as a consequence of FcγR-targeting. However, the inhibitory FcγRIIB had no impact on this enhancement. In conclusion, targeting Ag ex vivo to FcγR on DCs provides a method for enhanced Ag loading of DCs ex vivo, thereby reducing the amount of Ag required, while also avoiding the inhibitory impact of FcγRIIB. Thus, this represents a simple and less invasive strategy for increasing the potency of ex vivo-pulsed DC vaccines against chronic infectious diseases and cancer.
authors: Center for Immunology and Microbial Disease, 47 New Scotland Avenue, MC-151, Albany Medical College, Albany, NY 12208, United States.
authors: Giang H
authors: GH
authors: Pham
authors: Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, United States.
authors: Bibiana V
authors: BV
authors: Iglesias
authors: Center for Immunology and Microbial Disease, 47 New Scotland Avenue, MC-151, Albany Medical College, Albany, NY 12208, United States. Electronic address: gossele@mail.amc.edu.
authors: Edmund J
authors: EJ
authors: Gosselin
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D017951:Antigen Presentation; D000942:Antigens, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology*; D005604:Francisella tularensis; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D017452:Receptors, IgG / Q000276:immunology*; D014406:Tularemia / Q000517:prevention & control; D014611:Vaccination / Q000379:methods*
chemical_list: D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D016207:Cytokines; C080571:Fc gamma receptor IIB; D017452:Receptors, IgG
keywords: Cancer; Chronic infection; Dendritic cell vaccine; Fcγ receptor-targeted vaccine; Intranasal vaccine; Vaccine platform